Cumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy

Reuters

Feb 04

Cumberland Pharmaceuticals Wins FDA <a href="https://laohu8.com/S/FTRK">Fast Track</a> for Ifetroban in Duchenne Muscular Dystrophy

Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational oral therapy, ifetroban, targeting heart disease in patients with Duchenne muscular dystrophy (DMD). This designation is intended to facilitate the development and expedite the review of the drug for this serious and life-threatening condition. Cumberland previously reported positive results from its Phase 2 FIGHT DMD trial, which demonstrated a 5.4% improvement in left ventricular ejection fraction (LVEF) over 12 months of treatment with ifetroban.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL78092) on February 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608030367"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608030367\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608030367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608030367","market":"fut","top_or_hot":-1,"title":"Cumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Wins FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> for Ifetroban in Duchenne Muscular Dystrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational oral therapy, ifetroban, targeting heart disease in patients with Duchenne muscular dystrophy (DMD). This designation is intended to facilitate the development and expedite the review of the drug for this serious and life-threatening condition. Cumberland previously reported positive results from its Phase 2 FIGHT DMD trial, which demonstrated a 5.4% improvement in left ventricular ejection fraction (LVEF) over 12 months of treatment with ifetroban.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL78092) on February 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Wins FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> for Ifetroban in Duchenne Muscular Dystrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational oral therapy, ifetroban, targeting heart disease in patients with Duchenne muscular dystrophy (DMD). This designation is intended to facilitate the development and expedite the review of the drug for this serious and life-threatening condition. Cumberland previously reported positive results from its Phase 2 FIGHT DMD trial, which demonstrated a 5.4% improvement in left ventricular ejection fraction (LVEF) over 12 months of treatment with ifetroban.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL78092) on February 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1d8390:1","article_id":"2608030367","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608030367","pubTimestamp":1770213917,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration  has granted Fast Track Designation for its investigational oral therapy, ifetroban, targeting heart disease in patients with Duchenne muscular dystrophy . This designation is intended to facilitate the development and expedite the review of the drug for this serious and life-threatening condition. Cumberland previously reported positive results from its Phase 2 FIGHT DMD trial, which demonstrated a 5.4% improvement in left ventricular ejection fraction  over 12 months of treatment with ifetroban.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswir","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","CPIX":"坎伯兰药业","BK4007":"制药"},"translate_title":"Cumberland Pharmaceuticals赢得FDA伊非曲班治疗杜氏肌营养不良症的快速通道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPIX":0.9},"content_text":"Cumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy\n    \n\n        Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational oral therapy, ifetroban, targeting heart disease in patients with Duchenne muscular dystrophy (DMD). This designation is intended to facilitate the development and expedite the review of the drug for this serious and life-threatening condition. Cumberland previously reported positive results from its Phase 2 FIGHT DMD trial, which demonstrated a 5.4% improvement in left ventricular ejection fraction (LVEF) over 12 months of treatment with ifetroban.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL78092) on February 04, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}